RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.
NOD2
RICK/RIP2
inflammatory bowel diseases
Journal
International immunology
ISSN: 1460-2377
Titre abrégé: Int Immunol
Pays: England
ID NLM: 8916182
Informations de publication
Date de publication:
18 09 2019
18 09 2019
Historique:
received:
20
03
2019
accepted:
25
05
2019
pubmed:
28
5
2019
medline:
16
4
2020
entrez:
28
5
2019
Statut:
ppublish
Résumé
Previous studies have shown that inhibition of receptor-interacting serine/threonine kinase (RICK) (also known as RIP2) results in amelioration of experimental colitis. This role has largely been attributed to nucleotide-binding oligomerization domain 2 (NOD2) signaling since the latter is considered a major inducer of RICK activation. In this study, we explored the molecular mechanisms accounting for RICK-mediated inhibition of inflammatory bowel disease (IBD). In an initial series of studies focused on trinitrobenzene sulfonic acid (TNBS)-colitis and dextran sodium sulfate (DSS)-colitis we showed that down-regulation of intestinal RICK expression in NOD2-intact mice by intra-rectal administration of a plasmid expressing RICK-specific siRNA was accompanied by down-regulation of pro-inflammatory cytokine responses in the colon and protection of the mice from experimental colitis. Somewhat surprisingly, intra-rectal administration of RICK-siRNA also inhibited TNBS-colitis and DSS-colitis in NOD2-deficient and in NOD1/NOD2-double deficient mice. In complementary studies of humans with IBD we found that expression of RICK, cellular inhibitor of apoptosis protein 2 (cIAP2) and downstream signaling partners were markedly increased in inflamed tissue of IBD compared to controls without marked elevations of NOD1 or NOD2 expression. In addition, the increase in RICK expression correlated with disease activity and pro-inflammatory cytokine responses. These studies thus suggest that NOD1- or NOD2-independenent activation of RICK plays a major role in both murine experimental colitis and human IBD.
Identifiants
pubmed: 31132297
pii: 5499065
doi: 10.1093/intimm/dxz045
pmc: PMC6939834
doi:
Substances chimiques
Receptor-Interacting Protein Serine-Threonine Kinase 2
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
669-683Informations de copyright
© The Japanese Society for Immunology. 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cell Mol Immunol. 2010 Jul;7(4):288-95
pubmed: 20436512
Nature. 2002 Mar 14;416(6877):194-9
pubmed: 11894098
Immunol Rev. 2014 Jul;260(1):249-60
pubmed: 24942694
J Biol Chem. 2015 Aug 28;290(35):21244-51
pubmed: 26187467
Gastroenterology. 2011 Jan;140(1):231-41
pubmed: 20854823
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19440-5
pubmed: 18032608
Cancer Res. 2014 Nov 1;74(21):6119-28
pubmed: 25187386
J Immunol. 2017 May 15;198(10):3886-3896
pubmed: 28373582
J Biol Chem. 2005 Apr 15;280(15):14981-8
pubmed: 15691843
J Biol Chem. 2007 Dec 14;282(50):36223-9
pubmed: 17947236
J Biol Chem. 2002 Nov 1;277(44):41701-5
pubmed: 12194982
J Leukoc Biol. 2013 Nov;94(5):927-32
pubmed: 23794710
FASEB J. 2004 Oct;18(13):1550-2
pubmed: 15289440
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):443-9
pubmed: 25842225
Gut. 2003 Jun;52(6):840-6
pubmed: 12740340
Inflamm Bowel Dis. 2009 Aug;15(8):1145-54
pubmed: 19266573
Eur J Immunol. 2007 Aug;37(8):2317-25
pubmed: 17578844
Annu Rev Pathol. 2009;4:365-98
pubmed: 18928408
J Clin Invest. 2008 Feb;118(2):545-59
pubmed: 18188453
Eur J Immunol. 2008 Jan;38(1):64-72
pubmed: 18085666
J Med Chem. 2011 Apr 28;54(8):2714-26
pubmed: 21443232
Nature. 2002 Mar 14;416(6877):190-4
pubmed: 11894097
Gastroenterology. 2002 Jul;123(1):86-91
pubmed: 12105836
Immunity. 2006 Sep;25(3):473-85
pubmed: 16949315
Nat Rev Immunol. 2008 Jun;8(6):458-66
pubmed: 18500230
Int J Oncol. 2016 Jul;49(1):153-63
pubmed: 27210546
Inflamm Bowel Dis. 2008 Mar;14(3):295-302
pubmed: 18092345
J Med Chem. 2016 May 26;59(10):4867-80
pubmed: 27109867
Mucosal Immunol. 2011 Sep;4(5):484-95
pubmed: 21750585
Mol Oral Microbiol. 2017 Apr;32(2):131-141
pubmed: 27004566
Mucosal Immunol. 2016 Sep;9(5):1234-49
pubmed: 26813347
Nat Rev Immunol. 2014 Jan;14(1):9-23
pubmed: 24336102
BMC Infect Dis. 2014 Dec 02;14:648
pubmed: 25443778
J Biol Chem. 2014 Oct 24;289(43):29651-64
pubmed: 25213858
Nat Rev Immunol. 2006 Jan;6(1):9-20
pubmed: 16493424
Mucosal Immunol. 2014 Nov;7(6):1312-25
pubmed: 24670424
Immunity. 2018 Nov 20;49(5):873-885.e7
pubmed: 30366765
Immunity. 2012 Aug 24;37(2):326-38
pubmed: 22902233
PeerJ. 2016 Mar 31;4:e1843
pubmed: 27069792
EMBO Mol Med. 2013 Aug;5(8):1278-95
pubmed: 23818254
J Biol Chem. 2005 Apr 22;280(16):16278-83
pubmed: 15691841
Immunity. 2009 Jun 19;30(6):789-801
pubmed: 19464198
Gastroenterology. 2011 May;140(6):1756-1767
pubmed: 21530742
J Immunol. 2007 Feb 15;178(4):2380-6
pubmed: 17277144
Nat Immunol. 2013 Sep;14(9):927-36
pubmed: 23892723
BMC Genomics. 2007 Dec 20;8:472
pubmed: 18096043
Mol Cell Biol. 2007 Sep;27(17):6012-25
pubmed: 17562858
Biochim Biophys Acta. 2013 Dec;1832(12):2162-72
pubmed: 23851050